Citations

Clear

6273 citation(s) found for "To, Andrew".

Interpreting oblique impact data from an accelerometer-instrumented ice hockey helmet
Jorgensen, Janelle, Thoreson, Andrew R. , Stuart, Michael, Loyd, Andre M., Smith, Aynsley M., Twardowski, Casey P., Gaz, Daniel V., Hollman, John H. , An, Kai , Krause, David A. , An, Kai Nan, Stuart, Michael J. , Hollman, John

Mayo Clinic

Proceedings of the Institution of Mechanical Engineers, Part P: Journal of Sports Engineering and Technology | April 7, 2017 | Volume: 231 | Issue: 4 | Pages: 307-316

10.1177/1754337117700549 Get It

The purpose of this study was to assess the correlations of acceleration measurements between an instrumented hockey helmet and the Hybrid III headform and to determine whether collision with a broad surface affects the correlations between these data. A CCM Vector hockey helmet, instrumented with the Head Impact Telemetry System, was fitted onto an instrumented Hybrid III headform and dropped onto an inclined plate to simulate impacts in hockey. The helmet and headform were dropped from 0.15, 0.30, and 0.60 m at different orientations to create impacts to the vertex, occipital, right, left, and forehead surfaces. Peak linear and rotational acceleration magnitudes and head injury criteria were assessed for each system. Correlations were assessed with the Pearson correlation coefficient, and linear regression models were generated. Relative error was assessed, and results were compared with the Wilcoxon signed rank test. Peak acceleration magnitudes generally had strong mathematical correlations, although a 1:1 linear relationship for rotational acceleration data was not observed. Differences between helmet and head peak acceleration magnitudes were significant. The linear relationship varied according to the impact direction. Instrumented helmet and head data demonstrated a strong mathematical correlation, but measures of linear acceleration generally had better 1:1 agreement than rotational acceleration measures. There is some dependence in the relationship between the helmet and head data on the impact direction, with vertex strikes showing the weakest correlation. Although data generated from the helmet may be useful for interpreting head accelerations experienced by on-ice players, additional analysis of the time-series data should be performed to understand its full utility.
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes
Blumenfeld, Andrew , Silberstein, Stephen D., Aurora, Sheena K. , Brin, Mitchell F. , Binder, William J. , Dodick, David W.

Mayo Clinic

Headache: The Journal of Head and Face Pain | April 7, 2017 | Volume: 57 | Issue: 5 | Pages: 766-777

10.1111/head.13074 | PMID 28387038 Get It

Objective To provide clinically relevant insights on the identification of the muscles and techniques involved in the safe and effective use of onabotulinumtoxinA for chronic migraine prophylaxis. Background Although guidance on the use of onabotulinumtoxinA for chronic migraine is available, based on the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program, clinical experience has shown that insufficient understanding of the anatomy and function of the head and neck muscles may lead to undesirable outcomes and suboptimal efficacy. Design/Methods Each muscle involved in the standardized PREEMPT injection paradigm is reviewed with a thorough description of each muscle's anatomy (ie, muscle description and location, innervation, vascular supply) and function. Key insights based on clinical experience are also provided to help improve outcomes. Results The identification of the muscles in the PREEMPT injection paradigm should be based on each patient's unique anatomy and injections should be administered using the advised techniques. A thorough examination of the patient prior to treatment is also critical to determine if any preexisting conditions may increase the risk for unwanted outcomes and appropriate expectations should be communicated. Conclusions Thorough knowledge of the functional anatomy of the muscles involved in the standardized PREEMPT injection paradigm is critical to achieve the efficacy and safety observed in clinical trials. In addition, it is important to assess a patient's baseline condition to anticipate the risk for unwanted outcomes that may result from treatment.
Associations between elevated pre‐treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma
Binder, Moritz , O’Byrne, Megan M., Ansell, Stephen, Feldman, Andrew L. , Novak, Anne J. , Porrata, Luis F. , Link, Brian K. , Witzig, T.E. , Maurer, Matthew J. , Cerhan, James R. , Markovic, Svetomir N. , Witzig, Thomas E. , Feldman, Andrew L , Link, Brian K , Binder, Moritz

Mayo Clinic

American Journal of Hematology | April 6, 2017 | Volume: 92 | Issue: 8 | Pages: 752-758

10.1002/ajh.24758 | PMID 28383112 Get It

AbstractHigher ratios of the pre‐treatment peripheral blood absolute lymphocyte (ALC) to absolute monocyte counts (AMC) are associated with improved outcomes in lymphoma. Conversely, elevated pre‐treatment serum cytokines are associated with inferior outcomes. The relationship between pre‐treatment serum cytokines and ALC/AMC ratios remains unknown. We studied twelve serum cytokines and the ALC/AMC ratios in 390 patients with untreated diffuse large B‐cell, follicular, mantle cell, T‐cell, and Hodgkin lymphoma. Different pre‐treatment serum cytokine concentrations correlated with ALC, AMC, and ALC/AMC ratios depending on the lymphoma type. In the entire cohort (n = 390) lower ALC/AMC ratios modestly correlated with higher IL‐2R (r = −0.36), IL‐12 (r = −0.17), IP‐10 (r = −0.23), and MIG (r = −0.32) concentrations (p < 0.001). Elevated IL‐2R was independently associated with suppressed ALC (OR 2.69, 95% CI 1.77–4.07,p < 0.001), elevated AMC (OR 2.05, 95% CI 1.34–3.14,p < 0.001), and suppressed ALC/AMC ratios (OR 3.51, 95% CI 2.31–5.34,p < 0.001). Both elevated IL‐2R (HR 2.27, 95% CI 1.48–3.49,p < 0.001) and suppressed ALC/AMC ratios (HR 1.53, 95% CI 1.03–2.28,p = 0.037) were independently associated with inferior overall survival. These data support the notion that elevated serum cytokines are immunosuppressive and provide further rationale to target the tumor microenvironment for therapeutic benefit.
A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Jack, Clifford R., Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Sadowski, Martin, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Hsiung, Robin, Schultz, Susan, Burns, Jeffrey, Jicha, Gregory, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R. , Hsiung, Ging‐Yuek Robin , Jicha, Gregory A. , Sadowski, Martin , van Dyck, Christopher H, Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Schultz, Susan, Burns, Jeffrey, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1768-1775

10.1212/wnl.0000000000003904 | PMID 28381506 Get It

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheum
Rider, Lisa G. , Ruperto, Nicolino , Bayat, Nastaran, Amato, Anthony A. , Dastmalchi, Maryam, Katz, James D. , Mammen, Andrew L. , Visser, Marianne de, Ytterberg, Steven R. , Lundberg, Ingrid E. , Chung, Lorinda, Dankó, Katalin , Torre, Ignacio García‐De La , Villa, Luca, Rinaldi, Mariangela, Rockette, Howard E., Lachenbruch, Peter A., Miller, Frederick W. , Vencovský, Jiří , Rouster‐Stevens, Kelly , Huber, Adam M. , Selva-O’Callaghan, Albert , Rutkove, Seward B. , Dimachkie, Mazen M. , Olesińska, Marzena , Chung, Leland W.K. , Shinjo, Samuel Katsuyuki , Ramchandren, Sindhu , Saketkoo, Lesley Ann , Mann, H. , Aggarwal, Rohit , Erman, Brian , Feldman, Brian Michael , Oddis, Chester V. , Chinoy, Hector , Cooper, Robert G. , Fiorentino, David Franklin , Isenberg, David , Visser, Marianne de, Chung, Lorinda, Song, Yeong Wook , Mann, Heřman , Vencovsky, Jiri , Shinjo, Samuel Katsuyuki , Selva O'Callaghan, Albert , Chung, Lorinda , García-De La Torre, Ignacio , Dimachkie, Mazen M , Lundberg, Ingrid E , Pistorio, Angela

Mayo Clinic

Arthritis & Rheumatology | April 6, 2017 | Volume: 69 | Issue: 5 | Pages: 898-910

10.1002/art.40064 | PMID 28382787 Get It

ObjectiveTo develop response criteria for adult dermatomyositis (DM) and polymyositis (PM).MethodsExpert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus.ResultsConsensus was reached for a conjoint analysis–based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0–100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (P < 0.001).ConclusionThe response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute percent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Czuczman, Myron S., Trněný, Marek , Davies, Andrew , Rule, Simon , Linton, Kim , Wagner‐Johnston, Nina D. , Gascoyne, Randy D. , Slack, Graham W. , Eberhard, David A., Hernandez‐Ilizaliturri, Francisco J. , Salles, Gilles , Zinzani, Pier Luigi , Wright, George W. , Staudt, Louis M. , Yang, Yandan , Lih, Chih-Jian, Russo, Jacqueline, Thakurta, Anjan , Hagner, Patrick R. , Fustier, Pierre , Song, Dale, Lewis, Ian D., Brousset, Pierre , Witzig, Thomas E. , Williams, P. Mickey , Lih, Chih‐Jian, Zinzani, Pier Luigi , Salles, Gilles A , Davies, Andrew , Trnĕný, Marek , Linton, Kim M , Wright, George

Mayo Clinic

Clinical Cancer Research | April 5, 2017 | Volume: 23 | Issue: 15 | Pages: 4127-4137

10.1158/1078-0432.ccr-16-2818 | PMID 28381416 Get It

Abstract Purpose: Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Experimental Design: Patients with DLBCL who received ≥2 prior therapies were stratified by DLBCL subtype [germinal center B-cell (GCB) vs. non-GCB; determined by immunohistochemistry (IHC)] and then randomized 1:1 to lenalidomide (25 mg/day, 21 days of 28-day cycle) or IC (gemcitabine, rituximab, etoposide, or oxaliplatin). Crossover to lenalidomide was permitted for IC-treated patients with radiologically confirmed progressive disease. The primary endpoint was overall response rate (ORR). Progression-free survival (PFS), overall survival, and subtype analysis [GCB vs. activated B-cell (ABC)] using gene expression profiling (GEP) were exploratory endpoints. Results: Stage 1: 102 DLBCL patients (by IHC: non-GCB, n = 54; GCB, n = 48) received ≥1 dose of lenalidomide or IC. Hematologic treatment-emergent adverse events with lenalidomide versus IC included neutropenia (42.6%; 36.4%), anemia (33.3%; 47.3%), thrombocytopenia (24.1%; 43.6%), and leukopenia (5.6%; 12.7%), respectively. Overall, lenalidomide-treated patients had an ORR of 27.5% versus 11.8% in IC (ORRs were similar regardless of IHC-defined DLBCL subtype). Median PFS was increased in patients receiving lenalidomide (13.6 weeks) versus IC (7.9 weeks; P = 0.041), with greater improvements in non-GCB patients (15.1 vs. 7.1 weeks, respectively; P = 0.021) compared with GCB (10.1 vs. 9.0 weeks, respectively; P = 0.550). Conclusions: The clinical benefit of lenalidomide monotherapy in DLBCL patients was more evident in the non-GCB subtype. Exploratory analyses suggest that this preferential benefit was more pronounced in the GEP-defined ABC population, demonstrating a need for additional studies of lenalidomide in DLBCL using GEP subtyping. Clin Cancer Res; 23(15); 4127–37. ©2017 AACR.
Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene
Valla, Jon, Yaari, R. , Wolf, Andrew B. , Kusne, Yael , Beach, Thomas G. , Roher, Alex E., Corneveaux, Jason J., Huentelman, Matthew J. , Caselli, Richard J. , Reiman, Eric M.

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 22 | Issue: 1 | Pages: 307-313

10.3233/jad-2010-100129 | PMID 20847408 Get It

Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 ( 90 Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL)
Emmanouilides, Christos, Raubitschek, Andrew, Darif, Mohamed, Schilder, Russell J., Wiseman, Gregory A., Gordon, Leo I. , Molina, Aurelia Alañón , White, C. A., Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6574-6574

10.1200/jco.2004.22.90140.6574 Get It

Local excision for rectal cancer
Stewart, Andrew K., Nelson, Heidi, Baxter, Nancy Noel

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3615-3615

10.1200/jco.2004.22.90140.3615 Get It

Phase III trial of adjuvant immunotherapy with MOAb 17–1A following resection for stage II adenocarcinoma of the colon (CALGB 9581)
Colacchio, Thomas A., Warren, Robert S. , Benson, A. I. B., Goldberg, Richard M. , Hollis, Donna, Niedzwiecki, Donna , Compton, Carolyn C. , Kerr, Darcy A. , Fields, Andrew T. , Mayer, Robert J.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3522-3522

10.1200/jco.2004.22.90140.3522 Get It